Höchst: The European Commission approved €400 million of German state aid in September 2026 to protect insulin supply in Europe, and the measure pays Sanofi to keep and expand human insulin production in Frankfurt. The money compensates Sanofi-Aventis Deutschland for a public service obligation that the market would not deliver on its own. Without it, the company could close its German facility, and that closure would leave only one production site for these medicines across the European Economic Area.
Germany will provide the funds as public service compensation under EU state aid rules for services of general economic interest, and the Commission assessed the scheme against that framework. The case carries the number SA.115239, and a non-confidential version will appear in the Commission’s state aid register. Under the decision, Sanofi must build a new insulin factory at its Industriepark Frankfurt-Höchst site by 31 December 2032.
Production duties run much longer than construction. Sanofi must keep producing insulin at Frankfurt-Höchst until 31 December 2042, with output of at least 1.1 tonnes of insulin a year. The company must also hold a stockpile of one tonne of insulin active pharmaceutical ingredient and give priority to EEA markets whenever shortages strike.
The decision targets a dependence problem in insulin supply. If the German site closed, Europe would lose domestic production of certain insulin products and rely on imports from outside the EEA. People with diabetes cannot skip doses, so an interruption in insulin supply carries immediate clinical risk, which explains why governments now treat insulin as a strategic medicine.
The approval fits a wider push to secure essential medicines. The Critical Medicines Act proposal pursues the same goal of reducing shortages and cutting reliance on a handful of suppliers outside Europe. State aid offers a faster route for protecting insulin supply in individual cases, because a government can act on one fragile product line while the legislators debate general rules.
Approval shows that member states can use public money to keep strategic production at home when they demonstrate a real market failure and bind the beneficiary to long commitments. The production obligation through 2042 and the stockpile requirement give regulators concrete conditions to monitor, and the Commission will rely on those terms to judge whether the aid achieves its purpose.
For patients and pharmacists, the practical effect will take years to arrive because the new factory must be built first. Until the plant opens, the €400 million decision mainly signals that Berlin and the Commission accept that insulin supply is a matter of security. The way Sanofi meets its 2032 construction deadline will show whether public money can really secure insulin supply in Europe.
